HEMA QUEBEC has a total of 21 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 1999. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology and pharmaceuticals are INTROGENE BV, REGENERATIVE RES FOUNDATION and SHENZHEN ISTEM REGENERATIVE MEDICINE SCI TECH CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | United States | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | Canada | 3 | |
#5 | Australia | 2 | |
#6 | China | 1 | |
#7 | Israel | 1 | |
#8 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Therapeutic chemical compounds | |
#5 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Proulx Chantal | 8 |
#2 | Neron Sonia | 7 |
#3 | Dumont Nellie | 7 |
#4 | Lemieux Real | 6 |
#5 | Dupuis Nicolas | 4 |
#6 | Laganière Josée | 4 |
#7 | Fecteau Jessie Farah | 3 |
#8 | Laganiere Josee | 3 |
#9 | Roy Annie | 3 |
#10 | Drouin Mathieu | 1 |
Publication | Filing date | Title |
---|---|---|
US2018147239A1 | Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof | |
WO2011000116A1 | Use of steroidal compounds for the conversion of normal b lymphocytes into immunoglobulin-secreting plasma cells | |
WO2010034103A1 | Method for polyclonal immunoglobulin g production by human b cells | |
CA2562760A1 | A new method of expanding cord blood cells | |
EP1394183A1 | Purification of polyreactive autoantibodies and uses thereof | |
US6472208B1 | Method of producing human IFN-α using sendai virus-infected hematopoietic stem cells | |
CA2339323A1 | Primer-specific and mispair extension assay for identifying gene variation |